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Research Long-term progestin contraceptives (LTPOC) 
induce aberrant angiogenesis, oxidative stress and 
apoptosis in the guinea pig uterus: A model for 
abnormal uterine bleeding in humans
Graciela Krikun*1, Irina A Buhimschi1, Martha Hickey2, Frederick Schatz1, Lynn Buchwalder1 and Charles J Lockwood1
Abstract
Background: Irregular uterine bleeding is the major side effect of, and cause for, discontinuation of long-term 
progestin-only contraceptives (LTPOCs). The endometria of LTPOC-treated women display abnormally enlarged, fragile 
blood vessels (BV), decreased endometrial blood flow and oxidative stress. However, obtaining sufficient, good quality 
tissues have precluded elucidation of the mechanisms underlying these morphological and functional vascular 
changes.
Methods: The current study assessed the suitability of the guinea pig (GP) as a model for evaluating the uterine effects 
of LTPOC administration. Thus GPs were treated with a transdermal pellet for 21 days and examined for endometrial 
histology, angiogenic markers as well as markers of oxidative stress and apoptosis.
Results and Discussion: We now demonstrate that GP uteri were enlarged by both estradiol (E2) and 
medroxyprogesterone acetate (MPA) (p < 0.001). Effects of MPA on uterine weight differed significantly depending on 
E2 levels (p < 0.001), where MPA opposed the E2 effect in combined treatments. Angiogenesis parameters were 
similarly impacted upon: MPA alone increased BV density (p = 0.036) and BV average area (p = 0.002). The presence of 
E2 significantly decreased these parameters. These changes were associated with highly elevated of the lipid 
peroxidation product, 8-isoprostane (8-isoP) content in E2+MPA-treated and by nuclear 8-OH-deoxyguanosine (8oxoG) 
staining compared to all other groups (p < 0.001). Abnormalities in the E2+MPA group were consistent with chromatin 
redistribution, nuclear pyknosis, karyolysis and increased apoptosis as observed by a marked increase in TUNEL 
labeling.
Conclusions: LTPOC exposure alters endometrial vascular and tissue morphology consistent with oxidative stress and 
apoptosis in a complex interplay with endogenous estrogens. These findings are remarkably similar to in vivo change 
observed in the human uterus following LTPOC administration. Hence, the GP is an excellent model for the study of 
LTPOC effects on the uterus and will be extremely useful in determining the mechanistic pathways involved in this 
process which cannot be conducted on humans.
Introduction
Because of their safety and efficacy, long-term progestin-
only contraceptives (LTPOCs) are well-suited for women
with restricted access to health care or in whom estrogen
containing contraceptives are contraindicated. Unfortu-
nately, administration of LTPOCs leads to irregular uter-
ine bleeding in the majority of users [1,2]. Such bleeding
disturbances are the primary indication for discontinua-
tion of therapy[1,2].
Endometria from LTPOC-treated patients display
dilated, thin walled, fragile vessels that are irregularly dis-
tributed across the endometrial surface [3-5]. Previous
studies from our laboratory [6,7] as well as others [8-14]
demonstrated that LTPOC therapy produced a statisti-
cally significant increase in mean lumen diameter of
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microvessels at bleeding versus non-bleeding sites [7] and
that the key regulators of endometrial angiogenesis, vas-
cular endothelial growth factor (VEGF) and angiopoie-
tin-2 (Ang-2) were up-regulated in endometria treated
with LTPOC[6,9]. Moreover, we demonstrated that
hypoxia and reactive oxygen species (ROS) induced aber-
rant angiogenesis by reducing endometrial blood flow,
inducing hypoxia, decreasing the ratio of the angiostatic
agent, angiopoietin-1 to the angiogenic factor, angiopoie-
tin-2 [3,5,6].
While past studies produced descriptive information
regarding the possible causes of abnormal uterine bleed-
ing following LTPOC treatment, considerations of diffi-
culty in attaining good quality tissues from humans
preclude functional studies of the mechanistic pathways
involved in this process. Poor understanding of the mech-
anisms underlying bleeding has limited the development
of effective therapies for abnormal bleeding with LTPOC.
To further understand these mechanisms, we determined
whether the guinea pig (GP) was a relevant model to
study the uterine effects of LTPOC administration. The
GP was chosen because its endometria display functional
estrogen and progesterone receptors [15] as well as other
properties closely related to the humans including spon-
taneous estrous cycling and hemochorial placentation
[16-19]. In order to elucidate mechanisms underlying
LTPOC-induced abnormal uterine bleeding, we evalu-
ated the separate and interactive effects of estrogen and
progestin on GP-endometrial weight, vascular morphol-
ogy, oxidative stress and apoptosis.
Materials and methods
Guinea pigs
Eighteen nulliparous female GPs, aged 2-6 months, were
subjected to bilateral oopherectomy and then given sub-
cutaneous implants of 50 mg medroxyprogesterone ace-
tate (MPA)-cholesterol-based 21 day time-release pellets
or 5 mg estradiol (E2) cholesterol based 21 day time-
release pellets (Innovative Research of America; Sarasota,
FL) or both. Thus, animals received the treatment as fol-
lows: MPA (n = 6), E2 (n = 6), E2+MPA (n = 3) or placebo
(n = 3). After three weeks, hysterectomy was performed
and the right uterine horn was formalin fixed whereas the
left horn was snap frozen for subsequent studies. These
studies were approved by both Charles River (Wilming-
ton, MA) and Yale University IACUC offices.
Histology
The specimens were weighed and then formalin fixed,
and paraffin embedded. Five micron sections were cut
and stained with Hematoxylin-Eosin or Trichrome
Mason (Sigma-Aldrich, St. Louis, MO) by conventional
h i s t o l o g i c a l  p r o c e d u r e s  a s  d e s c r i b e d  [ 2 0 ]  o r  u s e d  f o r
immunohistochemistry as illustrated below.
Immunohistochemistry
Sections were stained for von Willebrand factor (vWF)
with the AB6994 primary antibody (Abcam, Cambridge,
MA) at 1-10,000 dilution or 8-oxoG with the x 24326 pri-
mary antibody at 1-100 (Oxis International, Foster City,
CA). For negative controls, normal IgG isotypes which
were derived from the animals from which the antibodies
were prepared and used at the same concentrations as the
primary antibody. The sections were washed and the
appropriate secondary biotinylated antibody (Vector
Laboratories, Inc., Burlingame, CA, USA) was added per
the manufacturer's instructions.
The antigen-antibody complex was detected with 3,3'-
diaminobenzidine with or without nickel sulfate as the
chromogen solution (Vector Laboratories). When nickel
sulfate was used, no hematoxylin counterstaining was
conducted. For each condition, 3 different slides were
assessed and at least three independent areas of each
slide photographed. For vWF, 6 randomly selected fields
were digitally captured at 200× magnification using an
Olympus microscope with digital camera. Vessel size,
density and heterogeneity were measured in each field by
computerized selection of the stained vessels with the
public domain image analysis software Image J as previ-
ously described by others [21,22]. All steps including field
acquisition and vessel morphology measurement were
performed blinded. For the other endpoints immunos-
taining intensities were ascertained with Image-J.
Lipid peroxidation profile
The isoprostanes are a family of eicosanoids of non-enzy-
matic origin produced by the random oxidation of tissue
phospholipids by oxygen radicals [5]. The levels of 8-IsoP
were measured in all 4 treatment groups on the frozen
uterine horn obtained as described above. The samples
were sonicated in 0.1 M Tris (pH 7.4) and diluted 1:5 in
eicosanoid affinity buffer (Cayman Chemical Company,
Ann Arbor, MI) and 8-isoP was detected by ELISA as we
previously described [5]. The sensitivity of this ELISA is
10 pg/ml. Limit of detection: 80% B/B0: 2.7 pg/ml
Apoptosis
Assessment of apoptosis was conducted on formalin-
fixed, paraffin-embedded tissues with ApoTag peroxidase
labeling kit (Chemicon International, Temecula, CA) as
per the manufacturer's instructions. The procedure is
based on detection of free 3'OH DNA termini in situ. To
assess differences in apoptotic levels, photographs were
taken from 3 representative areas of each slide at x200
magnitude under identical camera settings. The slides
were analyzed with Image J by setting the minimum
threshold that allowed for the visualization of the stained
nuclei only. This threshold was maintained throughout
the analysis of all subsequent slides. All values were sub-Krikun et al. Journal of Angiogenesis Research 2010, 2:8
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jected to analysis with Sigma Stat (Systat Software Inc,
Chicago, ILL) utilizing the recommended ANOVA pro-
vided by the program based on sample distribution. The
mean particle stained average +/- standard error of the
mean were then represented by bar graphs.
Statistical Analysis
Statistical analysis was conducted by ANOVA using the
Sigma Stat Program (SPSS Inc., Chicago, IL).
Results
Morphology
Figure 1 demonstrates that E2 (p < 0.001), MPA (p < 0.02)
and E2+MPA (p < 0.05) all increase uterine wet weight
compared with controls. The greatest effects were
observed with E2 treatment, consistent with the prolifer-
ative effects seen in human endometrial following estro-
gen-only treatment. As expected, the effects of MPA on
uterine weight differed significantly depending on E2 lev-
els, where MPA opposed the E2 effect in combined treat-
ments.
Histological analysis of the samples was conducted
after fixation and tissues were cut at 5 μ. Samples were
stained with H&E or Mason Trichrome (Figure 2). Sub-
endometrial edema is observed in MPA-treated animals.
Angiogenic parameters
Figure 3 displays staining for the endothelial marker, vWF
in endometria treated with placebo, E2, MPA or
E2+MPA. Based on that staining, the following endpoints
were analyzed as follows: Blood vessel density (BVD) =
area occupied by blood vessel lumen/area analyzed × 100.
Blood vessel size (BVS) = average blood vessel diameter
for the field analyzed (microns) and Blood vessel hetero-
geneity (BVH) = relative SD of blood vessel area for the
field analyzed (SD/average area × 100).
Thus, angiogenic parameters were impacted upon as
follows: MPA alone increased BV density (p = 0.036) and
Figure 1 Gross morphological analysis. A) Transverse and longitudinal sections of GP uteri following treatment with placebo, E2, MPA or E2+MPA 
as described in Methods. B) Bar graph represents the mean +/- standard error of the mean for 6 experiments as determined by ANOVA followed by 
Student-Newman-Keuls test. * p < 0.01, ** p = 0.25Krikun et al. Journal of Angiogenesis Research 2010, 2:8
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BV average area (p = 0.002). The presence of E2 signifi-
cantly decreased these parameters (BV density mean
SEM: CRL: 9.4 1.0%, E2: 10.3 1.6%, MPA: 13.6 1.1%,
E2+MPA: 6.0 0.7%, p = 0.002).
Oxidative stress
Levels of 8-isoprostane (8-IsoP) production were evalu-
ated in endometrial extracts obtained from uteri treated
with the various steroids. Figure 4 demonstrates that an
eight-fold elevation in 8-IsoP levels occurred in uteri
derived from E2+MPA-treated animals compared to all
other groups (p < 0.001). Figure 5 displays immunohis-
tochemical staining for 7,8-dihydro-8-oxoguanine (8-
oxoG) which reflects ROS damage to DNA [23]. It is
important to note however, that this endpoint alone is not
conclusive of oxidative damage but also necrosis. That is
Figure 2 Histological analysis. Samples were stained with H&E or Ma-
son Trichrome as described in Methods. Controls (CRL: Panels a-c). Sub-
endometrial edema is observed in MPA-treated animals (Panels d-f).
Figure 3 Vascular morphology: (Top) vWF staining was conducted on formalin fixed, paraffin embedded tissues for placebo. Bar graphs rep-
resents the mean +/- standard error of the mean for placebo control (CTL), E2, MPA or E2+MPA. A) Average blood vessel density, B) blood vessel size 
and C) blood vessel area heterogeneity. Statistical analysis were conducted by a two way ANOVA followed by Student-Newman-Keuls test for the 4 
treatment groups. (Bottom) From left to right, representative IHC of vWF for CTL, E2, MPA and E2+MPA (20×).Krikun et al. Journal of Angiogenesis Research 2010, 2:8
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why the study includes one of the best endpoints for oxi-
dative stress which is 8-isoP (see above)
Expression of 8-oxoG was significantly higher in
E2+MPA treated groups compared to E2 alone. A signifi-
cant, though diminished effect was observed with MPA
alone. However, no statistical differences were observed
between E2 and the placebo control.
Apoptosis
In humans, LTPOC treatment results in enhanced apop-
tosis of the endometrial glands and stroma [24]. Figure 6
demonstrates a similar apoptotic profile of E2+MPA
group as reflected by increased TUNEL labeling. By con-
trast, MPA did not displayed statistical differences in
TUNEL labeling compared to E2 or placebo.
Discussion
Endometria from LTPOC-treated patients display dilated
vessels that are irregularly distributed across the endome-
trial surface [3-5]. These dilated vessels bleed on minimal
pressure and have deficient vascular basement membrane
components [25,26] In the present studies we examined
the effects of hormone treatment on a guinea pig LTPOC
model. Because they undergo estrous cycling, the guinea
pig more closely emulates the reproductive system of
humans [27,28] compared to other rodents.
These studies demonstrate that treatment of guinea
pigs with progestin and in particular with E2+MPA
resulted in changes in endometrial vascular morphology,
as well as increased markers of apoptosis and oxidative
stress similar to that observed in human LTPOC-treated
endometria. In humans, LTPOC treatment occurs in the
Figure 4 Lipid peroxidation profile. The levels of 8-IsoP were mea-
sured in all 4 treatment groups as described in Methods. Bar graph rep-
resents the mean ELISA values +/- standard error of the mean. 
Statistical analysis were conducted by one way ANOVA with Student-
Newman-Keuls post hoc test (n = 6, *p < 0.001)
Figure 5 DNA oxidation. The levels of 8-oxoG were measured in all 4 treatment groups as described in Methods. (Top) Bar graph represents the av-
erage staining intensity/total field studied +/- standard error of the mean. Staining intensity was analyzed by Image J as previously described [21,22]. 
Statistical analysis were conducted by one way ANOVA with Student-Newman-Keuls post hoc test (n = 6, *p < 0.001 compared to E2). (Bottom) From 
left to right, representative IHC of 8oxoG for E2, MPA and E2+MPA (20×).Krikun et al. Journal of Angiogenesis Research 2010, 2:8
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setting of continuous low-level ovarian-derived estrogen
production. Since the GPs used in the current study are
ovariectomized, the E2+MPA treated animals are likely to
most closely resemble LTPOC-treated humans.
I n  p r i o r  s t u d i e s,  w e  h a v e  d e m o n s t r a t ed  t h a t  L T POC
results in both reduced endometrial blood flow and
increased oxidative stress [5,6]. These findings are associ-
ated with immunohistochemical evidence of increased
angiogenic factor production. Further, hypoxia and oxi-
dative stress induce increased production of vascular
endothelial growth factor (VEGF) and reduced produc-
tion of the angiostatic agent, angiopoietin-1 in cultured
human endometrial stromal cells [4,6,9]. Hypoxia and
oxidative stress also greatly enhance production of the
highly angiogenic molecule, angiopoietin-2, in cultured
endometrial endothelial cells [29]. However, it is unclear
how LTPOCs exert the initial vasoconstrictive effects on
human endometrium. The availability of this animal
model should allow dissection of the underlying mecha-
nism driving this vascular phenomenon. Information
gleaned from the experimental results presented in this
study are expected to ultimately improve the formula-
tions and acceptability of LTPOC therapies by reducing
aberrant angiogenesis and related irregular, unpredict-
able bleeding.
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